Gilead Sciences, Inc.
NASDAQ Global Select•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.Company Description
- CEO
- Mr. Daniel P. O'Day
- Full Time Employees
- 18,000
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Address
- 333 Lakeside Drive Foster City CA United States of America 94404
- IPO Date
- Invalid Date
- CIK
- 0000882095
- Website
- www.gilead.com
- Business
- Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
Company News
Got $200? 2 Healthcare Stocks to Buy and Hold Forever
Gilead Stock Rises as HIV Prevention Injection Meets Study Goals
Why Gilead Sciences Stock Thrashed the Market Today
Gilead's HIV-prevention drug cut infections by 96%, boosting stock
Gilead's twice-yearly shot cut HIV infections by 96% in trial
Gilead's Twice-Yearly Lenacapavir for HIV Prevention Reduced HIV Infections by 96% and Demonstrated Superiority to Daily Truvada® in Second Pivotal Phase 3 Trial
Gilead Sciences, Inc. (GILD) Baird Global Healthcare Conference (Transcript)
Undercovered Dozen: EPR Properties, Gilead, Portland General Electric, CNH Industrial +
Gilead Sciences, Inc. (GILD) Wells Fargo 2024 Healthcare Conference (Transcript)
Gilead Sciences, Inc. (GILD) Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
Merck's Death Cross Vs. Gilead's Golden Cross: Pharma Giants Diverge On Wall Street
Gilead Sciences Might Finally Be On Its Way To Higher Stock Prices
Gilead Sciences: Buy This Bargain Before It's Gone
Ipsen's Iqirvo Shows Strong Start in Primary Biliary Cholangitis, Now Faces Rivalry from Gilead's Livdelzi
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Gilead (GILD) Gains 16.8% in 3 Months: How Should You Play the Stock?
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
10 Great Dividend Stocks For The Next 10 Years
Gilead (GILD) Obtains FDA Approval for PBC Drug Livdelzi
Gilead Sciences alleges dangerous drug-counterfeiting operation at two NYC pharmacies in lawsuit